Trevi Therapeutics, Inc. (TRVI) 8-K Current Report — March 9, 2026
Filed: March 9, 2026
Health Care
Pharmaceutical PreparationsTrevi Therapeutics, Inc. (TRVI) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
Trevi Therapeutics, Inc. 8-K Mar 9, 2026 Event Analysis
Item 8.01 · Other Events
- • FDA End-of-Phase 2 meeting yielded full alignment on IPF-related chronic cough development plan — key regulatory de-risking milestone
- • Two pivotal Phase 3 trials to run in parallel: ~300-patient/52-week trial (primary endpoint at 24 weeks) + ~130-patient/12-week trial
Other Trevi Therapeutics, Inc. 8-K Filings
Get deeper insights on Trevi Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.